Evaluating the Association of Pregnancy-Related Plasma Protein A with Pregnancy Outcome: A Single-Center Retrospective Study

Authors

  • Asieh Khodami Department of Gynecology and Obstetrics, Shohada-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Sarang Younesi Prenatal Screening Department, Nilou Laboratory, Tehran, Iran
  • Masoumeh Mirzamoradi Prenatal Screening Department, Nilou Laboratory, Tehran, Iran
  • Parichehr Pooransari Prenatal Screening Department, Nilou Laboratory, Tehran, Iran
  • Soraya Saleh Gargari Prenatal Screening Department, Nilou Laboratory, Tehran, Iran
  • Zahra Naeiji Prenatal Screening Department, Nilou Laboratory, Tehran, Iran
  • Nayereh Rahmati Prenatal Screening Department, Nilou Laboratory, Tehran, Iran
  • Taraneh Arbabzadeh Prenatal Screening Department, Nilou Laboratory, Tehran, Iran
  • Mohammad Mahdi Taheri Amin Nilou Medical Laboratory, Tehran, Iran
  • Pourandokht Saadati Department of Gynecology and Obstetrics, Shohada-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Soudabeh Jamali Post Analytical Quality Control Department, Nilou Laboratory, Tehran, Iran
  • Fatemeh Aasdi Nilou Medical Laboratory, Tehran, Iran
  • Nikta Khalafi Nilou Medical Laboratory, Tehran, Iran
  • Mahmood Moosazadeh Gastrointestinal Cancer Research Center, Non-communicable Disease Institute, Mazandaran University of Medical Sciences, Sari, Iran

DOI:

https://doi.org/10.18502/jimc.v9i4.22461

Keywords:

Complication, Pregnancy, Plasma Protein A

Abstract

Background: Pregnancy-Associated Plasma Protein (PAPP-A) is a type of metalloproteinase that stimulates cell growth and plays a role in regulating the biological activity of Insulin-like Growth Factors (IGF). This enzyme plays an important role in the development of the fetus and placenta. Therefore, in this study, the relationship between the serum PAPP-A level and Maternal-fetal obstetrics abnormalities and aneuploidies disorders were examined.

Methods: Available data were used in this retrospective cohort study. The research population was made up of women with a history of pregnancy referring to Tajrish Martyrs’ Hospital in 2018, which was approximately 15,000 people. All the prenatal aneuploidy screening tests of these patients were done in Nilou Medical Laboratory a referral Laboratory in Tehran, Iran. The data was collected using a checklist that was prepared in advance. Based on this, the demographic data of the patients was collected.

Results: The results show that most of the patients with chromosomal abnormalities had a PAPP-A level of <0.27 (p<0.001). It was found that the group of patients whose PAPP-A level was > or =3 had the highest structural anomaly (p=0.021). On the other hand, the highest maternal adverse outcomes [such as Premature Rupture of Membranes (PROM), pre-eclampsia, abortion, polyhydramnios, oligohydramnios, amniotic leakage, bleeding, and blood spotting] were in patients whose PAPP-A level was <0.27 (p<0.001). No significant difference in adverse fetal outcomes was observed in the above three groups (p=0.61).

Conclusion: In general, it can be said that the decrease in PAPP-A serum levels in pregnant mothers can be associated with maternal and fetal adverse outcomes. The occurrence of these complications can increase the risk of T18 and T21 in patients.

Published

2026-09-01

Issue

Volume (9) issue (4)

Section

Articles